From the Delcath announcement:
"We found the presence of a liver metastasis with diameter ≥ 3 cm and elevated LDH level to be poor prognostic factors for OS"
Our trial had 4 patient >3cm and 46% with elevated LDH.
"Additionally, we excluded patients with elevated LDH levels at baseline, and it has been demonstrated that an elevated LDH is
associated with a poor OS in patients with metastatic ocular melanoma".
In our study, 8 out of the 13 patients had elevated LDH levels. The Delcath study excluded these patients altogether.
But the Delcath study is full of trial designs that specifically set things up in their favor in order to overinflated their result numbers.
Just another headline hit-job by the hypocrite that analyzes every word of the PVCT announcements in order to diminish the results, yet can't even do basic reading when trying to write headlines for others.
